News

Filter

Current filters:

Bristol-Myers Squibb

1 to 9 of 2887 results

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

24-03-2015

US pharma major Bristol-Myers Squibb has agreed to acquire from Danish diabetes care giant Novo Nordisk…

BiotechnologyBristol-Myers SquibbGlobalImmunologicalsLicensingNovo Nordisk

Ono Pharma gets South Korea approval of Opdivo

24-03-2015

Japanese drugmaker Ono Pharmaceutical has received approval from South Korea’s Ministry of Food and…

BiotechnologyBristol-Myers SquibbOncologyOno PharmaceuticalOpdivoRegulationSouth Korea

Most promising drugs of 2015 identified in new report

23-03-2015

Annual forecast finds significant increase in the number of blockbuster drug set to enter this year’s…

Bristol-Myers SquibbGlobalLCZ-696Markets & MarketingNovartisOpdivoPharmaceuticalPraluentRegeneron PharmaceuticalsSanofi

Russia’s R-Pharm in deals with AbbVie and Bristol-Myers for local production

21-03-2015

US drugmaker AbbVie has joined forces with Russia’s R-Pharm to establish the joint production of Kaletra…

AbbVieAnti-viralsBristol-Myers SquibbKaletra TabletsOncologyPharmaceuticalProductionR-PharmRussiaSprycel

Bristol-Myers’ daclatasvir NDA resubmission accepted by FDA

Bristol-Myers’ daclatasvir NDA resubmission accepted by FDA

13-03-2015

US pharma major Bristol-Myers Squibb says that its resubmitted New Drug Application for daclatasvir (proposed…

Anti-viralsBiotechnologyBristol-Myers SquibbdaclatasvirDaklinzaRegulationsofosbuvirUSA

NICE draft guidance recommends Eliquis for treating and preventing potentially fatal blood clots

NICE draft guidance recommends Eliquis for treating and preventing potentially fatal blood clots

06-03-2015

In draft guidance published today, the National Institute for Health and care Excellence (NICE), the…

Bristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPricingRegulationUK

US FDA expands use of Bristol-Myers’ Opdivo to NSCLC

US FDA expands use of Bristol-Myers’ Opdivo to NSCLC

05-03-2015

The US Food and Drug Administration late yesterday expanded the approved use of pharma major Bristol-Myers…

BiotechnologyBristol-Myers SquibbOncologyOpdivoRegulationUSA

Bristol-Myers will lead immuno-oncology market in 2022, say analysts

Bristol-Myers will lead immuno-oncology market in 2022, say analysts

04-03-2015

Analysts at Morningstar Equity Research see significantly more opportunity than the overall market for…

AstraZenecaBiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & CoOncologyOpdivoResearchRoche

1 to 9 of 2887 results

Back to top